Beta of Retrophin, Inc.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|SPRO Spero Therapeutics, Inc.||NASDAQ||3.77|
|LRN K12 Inc||NYSE > Consumer Services > Other Consumer Services||3.77|
|IAG Iamgold Corporation||NYSE > Basic Industries > Precious Metals||3.78|
|SILC Silicom Ltd||NASDAQ > Technology > Computer Communications Equipment||3.78|
|SUI Sun Communities, Inc.||NYSE > Consumer Services > Real Estate Investment Trusts||3.78|
|SGBX SG Blocks, Inc.||NASDAQ > Consumer Services > RETAIL: Building Materials||3.78|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.80|
|ORI Old Republic International Corporation||NYSE > Finance > Property-Casualty Insurers||226.11|
|KREF KKR Real Estate Finance Trust Inc.||NYSE > Consumer Services > Real Estate Investment Trusts||251.20|
|MAG MAG Silver Corporation||NYSEMKT > Basic Industries > Precious Metals||296.35|
|SLF Sun Life Financial Inc.||NYSE > Finance > Life Insurance||430.81|
|AMG Affiliated Managers Group, Inc.||NYSE > Finance > Investment Managers||965.40|
|IOR Income Opportunity Realty Investors, Inc.||NYSEMKT > Consumer Services > Real Estate Investment Trusts||4,830.80|